Eddingpharma to Start China Trial of Cardiome AFib Drug

Eddingpharm, a China in-licensing company, plans to start a China Phase I trial of Brinavess, a drug developed by Cardiome Pharma of Canada to treat atrial fibrillation. Eddingpharm will conduct the Phase I trial in healthy volunteers and then proceed to a Phase III trial, which it expects will begin before year-end. Eddingpharm in-licensed the drug in late 2014, paying $1 million upfront and agreeing to an additional $3 million in milestones. More details.... Stock Symbol: (NSDQ: CRME) Share this with colleagues: // //